Trial · NCT07914283
Implementation of a Person-Centered and Integrated Care Pathway for Hypertension
NCT07914283, Not applicable, Not yet recruiting, Region Stockholm
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Implementation of a Person-Centered and Integrated Care Pathway for Hypertension. Trials, record NCT07914283. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07914283
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Implementation of a Person-Centered and Integrated Care Pathway for Hypertension
- NCT number
- NCT07914283
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 120,000 participants, estimated
- Lead sponsor
- Region Stockholm
- Conditions
- Hypertension
- Interventions
- Educational intervention for doctors and nurses
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the proportion of patients with blood pressure <130/<80 mmHg | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals whose last recorded blood pressure was below the target according to the person-centered and integrated care pathway (PSVF) for hypertension (\<130/\<80 mmHg), irrespective of measurement method (office, home, or ambulatory blood pressure monitoring). The outcome is assessed in each 6-month interval, and the primary effect measure is the average effect over the first 12 months after each center's scheduled crossover. |
| Secondary | Change from baseline in the proportion of patients with their blood pressure measured | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension who, in each 6-month interval had their blood pressure measured |
| Secondary | Change from baseline in the proportion of patients who were dispensed statin therapy | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension who were dispensed statin therapy |
| Secondary | Change from baseline in the proportion of patients who achieved an office blood pressure <140/<90 mmHg, a home blood pressure <135/<85 mmHg, or an ambulatory blood pressure <135/<85 mmHg | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals who achieved an office blood pressure \<140/\<90 mmHg, a home blood pressure \<135/\<85 mmHg, or an ambulatory blood pressure \<135/\<85 mmHg. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover. |
| Secondary | Change from baseline in the proportion of patients who were dispensed combination therapy with antihypertensive agents | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more) |
| Secondary | Change from baseline in the proportion of patients who achieved LDL cholesterol targets according to the ESC guidelines | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who achieved LDL cholesterol targets according to the ESC guidelines (among patients with LDL cholesterol measured). Very high risk \<1.4 mmol/L; high risk \<1.8 mmol/L, moderate risk \<2.6 mmol/L). |
| Secondary | Observed population trajectory of the proportion of patients with hypertension below 130/80 mmHg | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Observed population trajectory describing the proportion of patients with hypertension below the PSVF target 130/80 mmHg per half-year from H1-2025 to H2-2028, using the last blood pressure in that half-year. If no measurement is recorded, the most recent value during the last 12 months is carried forward. Missing values will be regarded as not treated to target. This is a descriptive series with no model terms and no p-values. It shows the total change in the population, combining the secular trend and the rollout. |
| Secondary | Change from baseline in proportion of patients with uncontrolled blood pressure that received treatment intensification | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Proportion of patients with a diagnosis of hypertension and a last blood pressure \>= 130/80 mmHg in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more) |
| Secondary | Change in last measured systolic BP in mmHg per patient period | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Mean systolic blood pressure in patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover. |
| Secondary | Mean number of primary care contacts per patient | 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods | Resource utilization. Mean number of primary care contacts per patient per 6-month interval, by staff category, in total and with a hypertension diagnosis registered at the visit. Reported descriptively per sequence and period. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07914283
GET https://conductscience.org/api/trials/v1/NCT07914283/registered